TY - JOUR
T1 - An IQ Consortium Perspective on The Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on the Need for Nonhuman Primates in Biomedical Research, Production and Testing of Products and Devices (Update 2017)
AU - Adams, Khary
AU - Clemons, Donna
AU - Impelluso, Lynn Collura
AU - Lee, Donna
AU - Maguire, Sean
AU - Myers, Alexis
AU - Petursson, Christopher
AU - Schulingkamp, Robert
AU - Trouba, Kevin
AU - Wright, Matthew
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - The recent Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on “The need for nonhuman primates in biomedical research, production and testing of products and devices” (2017 SCHEER) highlights approaches that could significantly contribute to the replacement, reduction, and refinement of nonhuman primate (NHP) studies. Initiatives that have the potential to affect NHP welfare and/or their use are expected to be appropriate, fair, and objective and publicly disseminated information focused on NHPs in biomedical research, which includes toxicologic and pathologic research and testing, should be objectively evaluated by stakeholder scientists, researchers, and veterinarians. Thus, IQ Consortium member companies convened to develop an informed and objective response, focusing on identifying areas of agreement, potential gaps, or missing information in 2017 SCHEER. Overall, the authors agree that many positions in the 2017 SCHEER Opinion generally align with industry views on the use of NHPs in research and testing, including the ongoing need of NHPs in many areas of research. From the perspective of the IQ Consortium, there are several topics in the 2017 SCHEER that merit additional comment, attention, or research, as well as consideration in future opinions.
AB - The recent Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on “The need for nonhuman primates in biomedical research, production and testing of products and devices” (2017 SCHEER) highlights approaches that could significantly contribute to the replacement, reduction, and refinement of nonhuman primate (NHP) studies. Initiatives that have the potential to affect NHP welfare and/or their use are expected to be appropriate, fair, and objective and publicly disseminated information focused on NHPs in biomedical research, which includes toxicologic and pathologic research and testing, should be objectively evaluated by stakeholder scientists, researchers, and veterinarians. Thus, IQ Consortium member companies convened to develop an informed and objective response, focusing on identifying areas of agreement, potential gaps, or missing information in 2017 SCHEER. Overall, the authors agree that many positions in the 2017 SCHEER Opinion generally align with industry views on the use of NHPs in research and testing, including the ongoing need of NHPs in many areas of research. From the perspective of the IQ Consortium, there are several topics in the 2017 SCHEER that merit additional comment, attention, or research, as well as consideration in future opinions.
KW - (xeno)transplantation
KW - DruSafe (IQ Consortium Preclinical Safety Leadership Group)
KW - IQ
KW - SCHEER
KW - biomedical research
KW - infectious diseases
KW - neuroscience
KW - nonhuman primate
KW - ophthalmology
KW - safety
KW - scientific Opinion
KW - testing
KW - toxicology
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85068821773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068821773&partnerID=8YFLogxK
U2 - 10.1177/0192623319857976
DO - 10.1177/0192623319857976
M3 - Article
C2 - 31280699
AN - SCOPUS:85068821773
SN - 0192-6233
VL - 47
SP - 649
EP - 655
JO - Toxicologic Pathology
JF - Toxicologic Pathology
IS - 5
ER -